The conserved NUS-1/DHDDS complex links N-glycosylation to lipid and lysosomal homeostasis in C. elegans

Meixi Gong, Yilin Du, Wentao Zhao, Lingfan Zhu, Changfeng Jia, Y. Xie, Chen Liu, Wenfei Li, Pei Zhao, Zheng ZhangbioRxiv 2025 · DOI

Abstract

N-glycosylation, driven by the cis-prenyltransferase (cis-PT) complex—a NUS1 and DHDDS heterotetramer—is vital for proteome integrity. Despite being linked to severe congenital disorders of glycosylation (CDGs), the systemic role of NUS1/DHDDS remains elusive. Here, we characterize the conserved C. elegans cis-PT complex and uncover a critical crosstalk with global lipid metabolism. cis-PT deficiency induces catastrophic ER stress, global glycoprotein defects, and developmental failure. Mechanistically, NUS-1 physically interacts with the core oligosaccharyltransferase (OST) complex, directly coupling substrate synthesis to N-glycan transfer. Loss of NUS-1 or DHDDS causes systemic lipopenia, lysosomal dysfunction, and cholesterol sequestration, resulting from impaired N-glycosylation of key regulatory glycoproteins like SCAP. Utilizing CDG-associated CRISPR models, we resolve the molecular basis for cis-PT dysfunction, identifying interface disruption and catalytic impairment as distinct disease etiologies. These findings collectively reveal a critical and previously unappreciated crosstalk between protein glycosylation and global lipid metabolism, establishing a robust system to explore CDG pathology and therapeutic strategies.

Introduction

N-glycosylation is a fundamental biological process where sugar chains (glycans) are covalently attached to proteins to ensure proper folding, stability, and localization. This process is initiated in the endoplasmic reticulum (ER) and relies on a lipid carrier called dolichol. The synthesis of dolichol is governed by the cis-prenyltransferase (cis-PT) complex, a heterotetramer composed of NUS1 and DHDDS subunits.

In humans, mutations in these genes lead to Congenital Disorders of Glycosylation (CDGs), which manifest as severe multi-systemic issues including epilepsy, neurodegeneration, and developmental delays. However, studying the systemic impact of these mutations has been hampered by the embryonic lethality of knockout models in mammals. By utilizing the genetic tractability of C. elegans, researchers have now mapped the broader metabolic consequences of cis-PT dysfunction, revealing a surprising link between protein glycosylation and lipid homeostasis.

Substrate Channeling: The Physical Bridge

A central finding of this research is the discovery that the cis-PT complex does not operate in isolation. Using immunoprecipitation followed by mass spectrometry (IP-MS) and structural modeling via AlphaFold3, the study demonstrated that the NUS-1/DHDDS complex physically anchors to the core Oligosaccharyltransferase (OST) complex.

This physical association suggests a "substrate channeling" model. In this model, the lipid carrier (Dol-P) is synthesized by the cis-PT complex and immediately handed off to the OST machinery for glycan transfer. This proximity maximizes efficiency and ensures a steady flux of glycosylation. When this bridge is disrupted, the entire assembly line stalls, leading to catastrophic ER stress and global glycoprotein defects.

The Glyco-Lipid Crosstalk

Perhaps the most significant insight is the discovery of "lipopenia"—a severe loss of systemic fat—resulting from glycosylation failure. The researchers traced this metabolic collapse to the under-glycosylation of SCAP (known as SCP-1 in worms).

Under normal conditions, SCAP acts as a chaperone, escorting the master transcription factor SREBP (SBP-1) from the ER to the Golgi, where it is activated to trigger the expression of fat-synthesis genes. However, when the cis-PT complex is deficient, SCAP is not properly glycosylated, rendering it unable to transport SREBP. This effectively shuts down the cell's ability to synthesize neutral lipids, leading to a dramatic reduction in lipid droplet size and number.

Lysosomal Collapse and Cellular Stress

The study also highlights the critical role of glycosylation in maintaining lysosomal integrity. Glycosylation is essential for the stability of lysosomal membrane proteins, such as LMP-1. In cis-PT deficient models, the lack of proper glycosylation causes the lysosomal membrane to become permeable or "leaky."

This leakage results in a rise in lysosomal pH (loss of acidity) and the spilling of acidic contents into the cytoplasm. This triggers a futile, hyperactive autophagic response as the cell attempts to clear the damaged organelles, further exacerbating cellular stress.

Resolving Disease Etiologies

By using CRISPR/Cas9 to create "humanized" C. elegans models, the researchers were able to distinguish between different molecular causes of CDGs:

  1. NUS-1 R223H: This mutation disrupts the physical interface between the subunits, preventing the heterotetramer from forming correctly.
  2. DHDDS R48H: This mutation directly impairs the catalytic pocket where the lipid carrier is synthesized, though the complex may still form.

These findings demonstrate that while the clinical symptoms of CDGs may appear similar, the underlying molecular failures can differ significantly, suggesting that therapeutic approaches may need to be mutation-specific.

Conclusion

This research establishes C. elegans as a robust model for studying the systemic complexities of N-glycosylation disorders. By identifying the physical link between the cis-PT and OST complexes and the downstream effects on SCAP-mediated lipid metabolism, the study provides a new roadmap for understanding CDG pathology. Future work will explore whether stabilizing the cis-PT/OST interface or targeting the SREBP pathway could offer viable therapeutic strategies for patients suffering from these rare genetic conditions.

Summary updated

Abstract

Abstract N-glycosylation, driven by the cis -prenyltransferase ( cis -PT) complex, a NUS1 and DHDDS heterotetramer, is vital for proteome integrity. Despite being linked to severe congenital disorders of glycosylation (CDGs), the systemic role of NUS1/DHDDS remains elusive. Here, we characterize the conserved C. elegans cis -PT complex and uncover a critical crosstalk with global lipid metabolism. cis -PT deficiency induces catastrophic ER stress, global glycoprotein defects, and developmental failure. Mechanistically, NUS-1 physically interacts with the core oligosaccharyltransferase (OST) complex, directly coupling substrate synthesis to N-glycan transfer. Loss of NUS-1 or DHDDS causes systemic lipopenia, lysosomal dysfunction, and cholesterol sequestration, resulting from impaired N-glycosylation of key regulatory glycoproteins like SCAP. Utilizing CDG-associated CRISPR models, we resolve the molecular basis for cis -PT dysfunction, identifying interface disruption and catalytic impairment as distinct disease etiologies. These findings collectively reveal a critical and previously unappreciated crosstalk between protein glycosylation and global lipid metabolism, establishing a robust system to explore CDG pathology and therapeutic strategies.
BibTeX
@misc{gong2025conserved,
  author = {Meixi Gong and Yilin Du and Wentao Zhao and Lingfan Zhu and Changfeng JIA and Y. Xie and Chen Liu and Wenfei Li and Pei Zhao and Zheng Zhang},
  title = {{The conserved NUS-1/DHDDS complex links N-glycosylation to lipid and lysosomal homeostasis in <i>C. elegans</i>}},
  year = {2025},
  doi = {10.64898/2025.12.25.696488},
  howpublished = {bioRxiv},
}
Figure